Supplementary data – Mycoplasma hyorhinis vaccine strain – Nagy, 2026 (hdl:21.15109/ARP/3IIFGY)

View:

Part 1: Document Description
Part 2: Study Description
Part 5: Other Study-Related Materials
Entire Codebook

(external link)

Document Description

Citation

Title:

Supplementary data – Mycoplasma hyorhinis vaccine strain – Nagy, 2026

Identification Number:

hdl:21.15109/ARP/3IIFGY

Distributor:

ARP

Date of Distribution:

2026-03-25

Version:

1

Bibliographic Citation:

Nagy, Eszter Zsófia; Szeredi, Levente; Földi, Dorottya; Belecz, Nikolett; Kovács, Áron Botond; Sulyok, Kinga Mária; Grózner, Dénes; Wehmann, Enikő; Bányai, Krisztián; Marton, Szilvia; Tenk, Miklós; Kreizinger, Zsuzsa; Gyuranecz, Miklós, 2026, "Supplementary data – Mycoplasma hyorhinis vaccine strain – Nagy, 2026", https://hdl.handle.net/21.15109/ARP/3IIFGY, ARP, V1

Study Description

Citation

Title:

Supplementary data – Mycoplasma hyorhinis vaccine strain – Nagy, 2026

Identification Number:

hdl:21.15109/ARP/3IIFGY

Authoring Entity:

Nagy, Eszter Zsófia (HUN-REN Veterinary Medical Research Institute)

Szeredi, Levente (University of Veterinary Medicine, Department of Microbiology and Infectious Diseases)

Földi, Dorottya (HUN-REN Veterinary Medical Research Institute)

Belecz, Nikolett (HUN-REN Veterinary Medical Research Institute)

Kovács, Áron Botond (HUN-REN Veterinary Medical Research Institute)

Sulyok, Kinga Mária (HUN-REN Veterinary Medical Research Institute)

Grózner, Dénes (HUN-REN Veterinary Medical Research Institute)

Wehmann, Enikő (HUN-REN Veterinary Medical Research Institute)

Bányai, Krisztián (HUN-REN Veterinary Medical Research Institute)

Marton, Szilvia (HUN-REN Veterinary Medical Research Institute)

Tenk, Miklós (University of Veterinary Medicine, Department of Microbiology and Infectious Diseases)

Kreizinger, Zsuzsa (HUN-REN Veterinary Medical Research Institute)

Gyuranecz, Miklós (HUN-REN Veterinary Medical Research Institute)

Grant Number:

LP2022–6/2022

Grant Number:

RRF-2.3.1-21-2022-00001

Distributor:

ARP

Access Authority:

Kreizinger, Zsuzsa

Depositor:

Kaján, Győző László

Date of Deposit:

2026-03-25

Holdings Information:

https://hdl.handle.net/21.15109/ARP/3IIFGY

Study Scope

Keywords:

Agricultural Sciences, 1-Methyl-3-nitro-1-nitrosoguanidine, Live attenuated vaccine, Mycoplasma hyorhinis, NTG, Porcine, Temperature-sensitive strain

Abstract:

<b>Background</b> <i>Mycoplasma</i> (<i>M</i>.) <i>hyorhinis</i> causes substantial economic losses in swine. Currently, prevention and treatment rely on minimizing risk factors and administering antibiotics, as no vaccines are commercially available in Europe. However, antibiotics often cannot fully eliminate the bacteria. The development of an effective vaccine could lead to a potentially long-term control method. <b>Materials and methods</b> A temperature-sensitive <i>M. hyorhinis</i> strain was developed using 1-methyl-3-nitro-1-nitrosoguanidine (NTG) mutagenesis. The immunogenicity and efficacy of this vaccine candidate clone were evaluated in combination with an adjuvant. Three-week-old piglets were immunized with the candidate vaccine strain, and the vaccination site was monitored daily. At six weeks of age, the pigs were challenged intravenously on two subsequent days. Daily clinical examinations were conducted, with blood and nasal swabs collected weekly throughout the study for <i>M. hyorhinis</i> enzyme-linked immunosorbent assay (ELISA), real-time PCR analysis, and isolation. Three weeks post-challenge, the animals were euthanized for gross and histopathological examinations. Body temperature was recorded daily, and body weight was measured upon arrival, and then at six and nine weeks of age. <b>Results</b> Vaccination significantly reduced clinical signs (p = 0.03), as well as gross pathological (p = 0.01) and histopathological (p = 0.005) lesions compared with the positive control group. The vaccinated group exhibited an earlier and higher increase in <i>M. hyorhinis</i>-specific IgG antibody levels post-challenge than the positive control group. However, the vaccine candidate did not mitigate the impact of <i>M. hyorhinis</i> infection on the weight gain. After the challenge (days 21–42), both the vaccinated (p = 0.001) and the positive control (p = 0.003) groups exhibited reduced weight gain compared with the negative control group. <b>Discussion</b> Overall, the attenuated <i>M. hyorhinis</i> strain, combined with the adjuvant, provided protection against <i>M. hyorhinis</i> infection. These results form a basis for the development of a novel vaccine candidate that offers effective prevention.

Methodology and Processing

Sources Statement

Data Access

Notes:

<a href="http://creativecommons.org/licenses/by-nc/4.0">CC BY-NC 4.0</a>

Other Study Description Materials

Related Materials

The attenuated M2642 clone was deposited at the Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Inhoffenstraße 7B, 38124 Braunschweig, Germany) (Accession number: DSM 35229).

Related Studies

The sequences of the MycSu206 parent strain and the M2642 clone have been deposited in the GenBank database (BioProject number: PRJNA1203880). The attenuated M2642 clone was patented under number P2500036 at the Hungarian Intellectual Property Office.

Related Publications

Citation

Title:

Nagy EZ, Szeredi L, Földi D, et al. Development and efficacy test of a live, attenuated Mycoplasma hyorhinis vaccine candidate strain. Vaccine. 2026;75:128278. doi:10.1016/j.vaccine.2026.128278

Identification Number:

10.1016/j.vaccine.2026.128278

Bibliographic Citation:

Nagy EZ, Szeredi L, Földi D, et al. Development and efficacy test of a live, attenuated Mycoplasma hyorhinis vaccine candidate strain. Vaccine. 2026;75:128278. doi:10.1016/j.vaccine.2026.128278

Other Study-Related Materials

Label:

supplementary_tables_1-14.xlsx

Text:

Supplementary tables 1-14

Notes:

application/vnd.openxmlformats-officedocument.spreadsheetml.sheet

Other Study-Related Materials

Label:

supplementary_table_10.csv

Text:

Supplementary table 10. Gross pathological lesion scores of the pigs in the vaccinated, positive control, and negative control groups. Lesions were not observed in the negative control group.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_11.csv

Text:

Supplemetnary table 11. Histopathological lesion scores of the pigs in the vaccinated, positive control, and negative control groups.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_12.csv

Text:

Supplementary table 12. Optical density (OD) values of the Mycoplasma hyorhinis in-house ELISA in the vaccinated, positive control, and negative control groups.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_13.csv

Text:

Supplementary table 13. Results of the Mycoplasma hyorhinis qPCR from the samples taken during the gross pathological examination from the vaccinated, positive control, and negative control groups. The table also presents the quantification cycle (Cq) values of the positive samples and the organs where pathological lesions were observed (highlighted with a *).

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_14.csv

Text:

Supplementary table 14. Results of Mycoplasma hyorhinis isolation and multiple-locus variable-number tandem-repeat analysis (MLVA). MLVA was performed following established protocols.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_1A.csv

Text:

Supplementary table 1A. Mastermix compositions of the applied qPCR assays.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_1B.csv

Text:

Supplementary table 1B. Thermal protocols of the applied qPCR assays.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_2.csv

Text:

Supplementary table 2. Scoring system for the clinical signs.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_3.csv

Text:

Supplementary table 3. Scoring system for the pathological lesions and evaluation of the vaccination site.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_4.csv

Text:

Supplementary table 4. Scoring system for the histopathological lesions.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_5.csv

Text:

Supplementary table 5. Selection of the 1-methyl-3-nitro-1-nitrosoguanidine (NTG) treated, temperature-sensitive (ts+) Mycoplasma hyorhinis clone.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_6.csv

Text:

Supplementary table 6. Detailed information on the polymorphisms (deletions, insertions, and Single Nucleotide Polymorphisms (SNPs)) in the genome of the temperature-sensitive (ts+) Mycoplasma hyorhinis clone compared to its parent strain.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_7.csv

Text:

Supplementary table 7. Body temperature changes of the pigs during the immunization and the challenge.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_8.csv

Text:

Supplementary table 8. Clinical sign scores of the vaccinated, positive control, and negative control pigs. Clinical signs were not observed in the negative control group.

Notes:

text/csv

Other Study-Related Materials

Label:

supplementary_table_9.csv

Text:

Supplementary table 9. Weight gain (kg) during the experiment in the vaccinated, positive control, and negative control groups.

Notes:

text/csv